ETF Securities CURE ETF (ASX:CURE)

The ETFS CURE ETF provides investors with exposure to the US biotechnology sub-industry within the health care sector. CURE adopts an equally weighted strategy, which allocates greater exposure to small and mid-cap shares compared to a market capitalisation weighted approach.

CURE ETF data

Ticker code: CURE
Yearly fee (MER): 0.45%
FUM: $23.38 million
Monthly spread: 0.42%
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
Range: 1 mth | 3 mths | 6 mths | 1 yr | 2 yrs | 5 yrs | 10 yrs

share price:

Prices updated using end of day data. Capital return only. FUM, fee and spread data updated monthly.

What does the CURE invest in?

The CURE ETF invests in biotechnology stocks trading on major US exchanges. CURE tracks the performance of the S&P Biotechnology Select Industry Index by holding all of the shares that make up the index, closely in proportion to their index weights. These companies are classified as belonging to the GICS biotechnology sub-industry, and must meet certain market capitalisation and liquidity requirements.

What do investors use CURE for?

CURE could be used by investors to get tactical exposure to a basket of companies within the USA’s biotechnology industry. Most biotech companies are heavily research-focused and their success can often depend on one breakthrough or regulatory approval, making it a speculative industry.

CURE dividend information

Distributions

A yearly or annual distribution means the ETF or managed fund expects to return income (generated by the fund) or excess capital gains back to you, the investor, once per year.

DRP Status

A ‘full or partial’ Distribution Reinvestment Plan (DRP) means the ETF or managed fund allows you, the investor, to take none, some or all of your monthly, quarterly, half-yearly or yearly distributions as new units in the ETF/fund.

Fund Issuer

ETF Securities is Australia’s second-oldest ETF business. Founded by Graham Tuckwell in 2003, ETF Securities has grown to become one of the leaders in the Australian ETF market.

Best ETFs warnings

The following warnings are applied by our team, based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.

When an ETF does not have a sufficiently long track record — typically, we consider this to be at least 3 years — the ETF could be at a higher risk of being closed down (if it doesn’t grow), and the historical performance and returns (if any) cannot be relied upon.

Tax Domicile

When a fund/ETF has a “domicile” of Australia it means it is a registered fund in Australia for tax purposes. This means investors who buy into this fund or ETF, and are Australian residents for tax purposes, will be subject to Australian taxes and regulation. 

Registry

Computershare is not only the largest share registry in Australia but also the world. The company was founded in 1978 as one of Melbourne’s first start-up technology companies, initially providing computer services to businesses.

Sector Information

The Best ETFs global or international shares sector includes ETFs, managed funds and index funds which cover international equities/share markets.

Looking for something better?

This brilliant (and free!) report is issued by Best ETFs Australia, a division of The Rask Group Pty Ltd. It is not a recommendation.
Speak to a financial professional before relying on this information and please read our Financial Services Guide (FSG).

General Financial Advice warning
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.

© Rask Australia 2020

feedback-icon

What can we do better? Please give us us some feedback :)

We care about your experience, please let us know if you have any suggestions to improve our site.